Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Metformin
|
| gptkbp:activities |
Decreases hepatic glucose production
Increases insulin sensitivity |
| gptkbp:affects |
Weight loss
Improved lipid profile Reduced cardiovascular risk |
| gptkbp:approves |
gptkb:1994
gptkb:FDA |
| gptkbp:brand |
gptkb:Glucophage_XR
gptkb:Fortamet Glumetza Riomet ER |
| gptkbp:category |
Category B
|
| gptkbp:class |
Biguanide
|
| gptkbp:clinical_trial |
Phase IV
Combination therapy Monotherapy |
| gptkbp:contraindication |
Severe renal impairment
Metabolic acidosis Hypersensitivity to metformin |
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:form |
Extended-release capsule
Oral solution |
| gptkbp:formulation |
Extended-release tablet
|
| gptkbp:has_ability |
500 mg
1000 mg 750 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Metformin ER
|
| gptkbp:ingredients |
gptkb:Metformin
|
| gptkbp:interacts_with |
Alcohol
Cationic drugs |
| gptkbp:is_monitored_by |
Blood glucose levels
Renal function |
| gptkbp:is_used_for |
Type 2 diabetes
|
| gptkbp:lifespan |
6.2 hours
|
| gptkbp:manager |
Oral
|
| gptkbp:manufacturer |
gptkb:Various
|
| gptkbp:scholarships |
Take with food
Do not crush or chew |
| gptkbp:side_effect |
gptkb:Nausea
Diarrhea Abdominal pain Vitamin B12 deficiency Gastrointestinal upset Lactic acidosis Hypoglycemia (rarely) |
| gptkbp:storage |
Room temperature
Protect from moisture |